^
    1d
    Case Report: CD19 CAR-T therapy induces durable remission in a pediatric patient with TP53-mutated, refractory Burkitt lymphoma: a 30-month follow-up. (PubMed, Front Oncol)
    This case, among the youngest reported uses of commercial Axi-cel for BL, highlights the diagnostic complexity in adolescent lymphoma and demonstrates that CD19 CAR-T therapy can overcome TP53-associated chemoresistance in adolescent BL. It also suggests that integrating molecular profiling and immunotherapy may provide new strategies for managing high-risk, treatment-refractory cases in the adolescent and young adult population.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Yescarta (axicabtagene ciloleucel)
    1d
    Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) (clinicaltrials.gov)
    P2, N=14, Not yet recruiting, AbbVie
    New P2 trial
    |
    Venclexta (venetoclax)
    1d
    Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) (clinicaltrials.gov)
    P2, N=74, Active, not recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    purinostat
    1d
    LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Nov 2033 | Trial primary completion date: Dec 2025 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    1d
    GLO-PACT: Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, American University of Beirut Medical Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Columvi (glofitamab-gxbm)
    1d
    Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene (clinicaltrials.gov)
    P1/2, N=50, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Sep 2027 --> Jan 2030 | Initiation date: Mar 2026 --> Oct 2026 | Trial primary completion date: Sep 2027 --> Jan 2030
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    pidnarulex (CX-5461)
    1d
    HCB101-101: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors (clinicaltrials.gov)
    P1, N=80, Recruiting, FBD Biologics Limited | N=60 --> 80
    Enrollment change
    |
    HCB101
    1d
    Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    1d
    Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) (clinicaltrials.gov)
    P3, N=132, Recruiting, Ono Pharmaceutical Co. Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • temozolomide • Velexbru (tirabrutinib)
    2d
    BRAWM: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, Sunnybrook Health Sciences Centre | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine
    2d
    XBP1-driven proliferative B cell subcluster in Diffuse Large B Cell Lymphoma linked to altered nucleotide metabolism. (PubMed, Eur J Med Res)
    This analysis has identified and characterized the proliferation-related B cells in DLBCL, which may provide some ideas for the treatment strategies in immune-oncology and cellular therapies.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD74 (CD74 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • XBP1 (X-box-binding protein 1)